{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T03:34:16Z","timestamp":1789097656185,"version":"build-2803163510"},"reference-count":18,"publisher":"Japanese Society of Internal Medicine","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2018]]},"DOI":"10.2169\/internalmedicine.9013-17","type":"journal-article","created":{"date-parts":[[2017,10,10]],"date-time":"2017-10-10T22:13:19Z","timestamp":1507673599000},"page":"65-70","source":"Crossref","is-referenced-by-count":12,"title":["The Effects of Mitiglinide and Repaglinide on Postprandial Hyperglycemia in Patients Undergoing Methylprednisolone Pulse Therapy"],"prefix":"10.2169","volume":"57","author":[{"given":"Kenichi","family":"Tanaka","sequence":"first","affiliation":[{"name":"First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Okada","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Mori","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Torimoto","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Arao","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Zang S, Ponto KA, Kahaly GJ. Intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab 96: 320-332, 2011."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Yang Z, Laubach VE, French BA, Kron IL. Acute hyperglycemia enhances oxidative stress and exacerbates myocardial infarction by activating NADPH oxidase during reperfusion. J Thorac Cardiovasc Surg 137: 723-729, 2009.","DOI":"10.1016\/j.jtcvs.2008.08.056"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Clore JN, Thurby-Hay L. Glucocorticoid-induced hyperglycemia. Endocr Pract 15: 469-474, 2009.","DOI":"10.4158\/EP08331.RAR"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. McDonough AK, Curtis JR, Saag KG. The epidemiology of glucocorticoid-associated adverse events. Curr Opin Rheumatol 20: 131-137, 2008.","DOI":"10.1097\/BOR.0b013e3282f51031"},{"key":"5","unstructured":"5. Lansang MC, Hustak LK. Glucocorticoid-induced diabetes and adrenal suppression: how to detect and manage them. Cleve Clin J Med 78: 748-756, 2011."},{"key":"6","unstructured":"6. Terui T, Murakami K, Niitsu Y. Nateglinide efficacy in two subjects with glucocorticoid-induced hyperglycemia. Prog Med 20: 1645-1648, 2000 (in Japanese)."},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Boyne MS, Silver DM, Kaplan J, et al. Timing of changes in interstitial and venous blood glucose measured with a continuous subcutaneous glucose sensor. Diabetes 52: 2790-2794, 2003.","DOI":"10.2337\/diabetes.52.11.2790"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Wise JK, Hendeler R, Feilig P. Influence of glucocorticoids on glucagon secretion and plasma amino acid concentrations in man. J Clin Invest 52: 2774-2782, 1973.","DOI":"10.1172\/JCI107473"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Lambillote C, Gilon P, Henquin JC. Direct glucocorticoid inhibition of insulin secretion. An in vitro study of dexamethasone effects in mouse islets. J Clin Invest 99: 414-423, 1997.","DOI":"10.1172\/JCI119175"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Feldman-Billard S, Kassaei R, Benrabah R, et al. Glucose tolerance of high-dose intravenous methylprednisolone therapy in ophthalmology. J Fr Opthalmol 27: 160-161, 2004.","DOI":"10.1016\/S0181-5512(04)96111-6"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Tamez Perez HE, G\u00f3mez de Ossio MD, Quintanilla Flores DL, et al. Glucose disturbances in non-diabetic patients receiving acute treatment with methylprednisolone pulses. Rev Assoc Med Bras 58: 125-128, 2012.","DOI":"10.1590\/S0104-42302012000100025"},{"key":"12","unstructured":"12. Tentoloutis N, Voulgari C, Katsilambros N. A review of nateglinide in the management of patients with type 2 diabetes. Vasc Health Risk Manag 3: 797-807, 2007."},{"key":"13","unstructured":"13. Malaisse WJ. Mitiglinide: a rapid- and short-acting non-sulfonylurea insulinotropic agent for the treatment of type 2 diabetic patients. Expert Opin Pharmacother 9: 2691-2698, 2008."},{"key":"14","unstructured":"14. Scott LJ. Repaglinide: a review of its use in type 2 diabetes mellitus. Drugs 72: 744-745, 2012."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Li Y, Xu L, Shen J, et al. Effects of short-term therapy with different insulin secretagogues on glucose metabolism, lipid parameters and oxidative stress in newly diagnosed type 2 diabetes mellitus. Diabetes Res Clin Pract 88: 42-47, 2010.","DOI":"10.1016\/j.diabres.2009.12.017"},{"key":"16","unstructured":"16. Rosenstock J, Hassman DR, Madder RD, et al.; Repaglinide Versus Nateglinide Comparison Study Group. Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes Care 27: 1265-1270, 2004."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Gao X. Multicentre, double-blind, randomized study of mitiglinide compared with nateglinide in type 2 diabetes mellitus patients in China. J Int Med Res 37: 812-821, 2009.","DOI":"10.1177\/147323000903700324"},{"key":"18","unstructured":"18. Malaisse WJ. Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus. Treat Endocrinol 2: 401-414, 2003."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/1\/57_9013-17\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T12:40:08Z","timestamp":1570192808000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/1\/57_9013-17\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.9013-17","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}